[{"address1": "535 W 24th Street", "address2": "5th Floor", "city": "New York", "state": "NY", "zip": "10011", "country": "United States", "phone": "(855) 508-3568", "website": "https://www.neurogene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.", "fullTimeEmployees": 91, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rachel L. McMinn Ph.D.", "age": 50, "title": "Founder, Executive Chair & CEO", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 676542, "exercisedValue": 0, "unexercisedValue": 203486}, {"maxAge": 1, "name": "Ms. Christine Mikail Cvijic J.D.", "age": 45, "title": "President, CFO & Corporate Secretary", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 623289, "exercisedValue": 0, "unexercisedValue": 658819}, {"maxAge": 1, "name": "Dr. Stuart  Cobb Ph.D.", "age": 53, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 478807, "exercisedValue": 0, "unexercisedValue": 338906}, {"maxAge": 1, "name": "Mr. Arvind  Sreedharan", "title": "Senior Vice President of Business Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Donna M. Cochener-Metcalfe J.D.", "age": 48, "title": "Senior VP & General Counsel", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Effie  Albanis M.D.", "title": "Senior Vice President of Early Clinical & Translational Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew E. Mulberg CPI, FAAP, M.D.", "title": "Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ricardo  Jimenez", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julie  Jordan M.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 23.3, "open": 23.06, "dayLow": 19.82, "dayHigh": 23.7, "regularMarketPreviousClose": 23.3, "regularMarketOpen": 23.06, "regularMarketDayLow": 19.82, "regularMarketDayHigh": 23.7, "forwardPE": -5.2461534, "volume": 313545, "regularMarketVolume": 313545, "averageVolume": 437591, "averageVolume10days": 364890, "averageDailyVolume10Day": 364890, "bid": 20.46, "ask": 20.65, "bidSize": 100, "askSize": 100, "marketCap": 303927136, "fiftyTwoWeekLow": 14.42, "fiftyTwoWeekHigh": 74.49, "priceToSalesTrailing12Months": 328.5699, "fiftyDayAverage": 20.926, "twoHundredDayAverage": 34.653, "currency": "USD", "enterpriseValue": 117413408, "floatShares": 4052058, "sharesOutstanding": 14854700, "sharesShort": 914186, "sharesShortPriorMonth": 1896815, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0704, "heldPercentInsiders": 0.10694, "heldPercentInstitutions": 1.10723, "shortRatio": 7.15, "shortPercentOfFloat": 0.0787, "impliedSharesOutstanding": 14854700, "bookValue": 14.506, "priceToBook": 1.4104508, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": 2364000, "trailingEps": -4.09, "forwardEps": -4.64, "lastSplitFactor": "1:4", "lastSplitDate": 1702944000, "enterpriseToRevenue": 126.933, "enterpriseToEbitda": -1.793, "52WeekChange": -0.29787236, "SandP52WeekChange": 0.19995654, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "NGNE", "underlyingSymbol": "NGNE", "shortName": "Neurogene Inc.", "longName": "Neurogene Inc.", "firstTradeDateEpochUtc": 1394202600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "51d6a4c2-efb6-34ae-b4ed-f6ab994594b8", "messageBoardId": "finmb_602062523", "gmtOffSetMilliseconds": -18000000, "currentPrice": 20.46, "targetHighPrice": 72.0, "targetLowPrice": 45.0, "targetMeanPrice": 52.8, "targetMedianPrice": 46.0, "recommendationMean": 1.28571, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 153904992, "totalCashPerShare": 11.845, "ebitda": -65467000, "totalDebt": 13785000, "quickRatio": 11.822, "currentRatio": 12.174, "totalRevenue": 925000, "debtToEquity": 8.893, "revenuePerShare": 0.106, "returnOnAssets": -0.32361, "returnOnEquity": -0.41339, "grossProfits": -52050000, "freeCashflow": -34067876, "operatingCashflow": -66083000, "operatingMargins": -21.766489, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]